Product Description
Cetuximab is a type of targeted cancer drug. It is also known by its brand name Erbitux. You might have it as a treatment for advanced bowel cancer and head and neck cancers that start in the mouth and throat. It is a type of monoclonal antibody. Monoclonal antibodies (MABs) are copies of a single antibody. They are made in the laboratory. Monoclonal antibodies seek out cancer cells by targeting particular proteins on the cell surface. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/cetuximab)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Iran, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 72
Highest Development Phases
Phase 3: Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma
Phase 2: Adenocarcinoma|Appendiceal Cancer|Cervical Cancer|Esophageal Cancer|Intestinal Cancer|Laryngeal Cancer|Mouth Cancer|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Oncology Unspecified|Oropharyngeal Cancer|Paranasal Sinus Cancer|Small Cell Lung Cancer|Uterine Cancer
Phase 1: Epilepsy|Gaucher Disease|Muscle Spasticity|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2024-03107 | P1 |
Recruiting |
Colorectal Cancer |
2029-01-18 |
|
| KAIROS | P2 |
Active, not recruiting |
Oncology Unspecified |
2028-11-22 |
|
| NCI-2023-06254 | P1 |
Recruiting |
Colorectal Cancer |
2028-03-28 |
|
| FIERCE-HN | P3 |
Recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2027-08-01 |